Back to News
Feb 26, 2026 4:00 PM

Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2

Eli Lilly and Co. (NYSE:LLY) shares are down on Thursday. The company announced promising results for its oral GLP-1 medication, orforglipron.

On Thursday, the Zepbound maker shared detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating orforglipron, an oral GLP-1, compared with Novo Nordisk A/S’ (NYSE:NVO) oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants.

Lilly’s Oral Drug Outperforms Novo Nordisk’s Drug

In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C (blood sugar) and weight.

In the latest news, Eli Lilly reported that orforglipron 36 mg significantly outperformed oral semaglutide 14 mg in a Phase 3 trial, achieving a 2.2% reduction in A1C compared to ...